Expression of interleukin-1 beta, tumor necrosis factor alpha, interleukins-6, -10 and -4, and metalloproteases by freshly isolated mononuclear cells from early never-treated and non-acute treated rheumatoid arthritis patients

Clin Exp Rheumatol. 1999 Sep-Oct;17(5):575-83.

Abstract

Objective: To determine IL-1 beta, TNF alpha, IL-6, IL-4, IL-10, MMP-1, MMP-3 and MMP-13 expression by freshly isolated peripheral blood (PBMC) and synovial fluid mononuclear cells (SFMC) in early, never-treated (ENT-RA) and non-acute, treated rheumatoid arthritis (NAT-RA) patients. To elucidate whether excessive or inadequate interleukin (IL) and metalloprotease (MMP) expression is influenced by the disease duration.

Methods: Fourteen RA patients, 7 with early RA (< 1 year of evolution) never treated with corticosteroids or disease-modifying antirheumatic drugs, and 7 patients with non-acute RA (> 2 years of evolution) treated with disease-modifying antirheumatic drugs, were studied by ELISA and quantitative and semiquantitative RT-PCR. A group of 14 healthy subjects matched for sex and age was included.

Results: No statistically significant difference in the protein or transcript levels for the cytokines of interest was found between the ENT-RA and NAT-RA groups. The cytokine mRNA expression by freshly isolated PBMC and SFMC in both groups was as follows: IL-1 beta > TNF alpha > IL-10 > IL-6, with no mRNA IL-4 expression. In contrast, cytokine serum levels in ENT-RA and NAT-RA patients were detected in inverse order as follows: IL-6 > IL-10, while IL-1 beta, TNF alpha and IL-4 were undetectable. MMP-3 mRNA expression by the PBMC of NAT-RA patients was statistically different to that in ENT-RA patients. Similar levels of mRNA expression of MMP-1, MMP-3 and MMP-13 by the PBMC and SFMC in both RA groups were observed.

Conclusions: A close equilibrium between MMP and pro/anti-inflammatory cytokine production is observed in ENT-RA and NAT-RA patients. This balance is apparently not influenced by the length of the disease. Highly sensitive methods such as quantitative RT-PCR and ELISA, and even studying freshly isolated MC, showed sustained cytokine secretion at the local level (synovial fluid/SFMC) and scarce translation at the peripheral level (serum/PBMC). Expression of MMP mRNA needs to be further evaluated in order to know whether their peripheral expression reflects their local activity in RA patients.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acute Disease
  • Adult
  • Antirheumatic Agents / administration & dosage
  • Antisense Elements (Genetics)
  • Arthritis, Rheumatoid / drug therapy
  • Arthritis, Rheumatoid / genetics
  • Arthritis, Rheumatoid / immunology*
  • Chronic Disease
  • Collagenases / genetics*
  • Female
  • Gene Expression Regulation, Enzymologic / immunology
  • Humans
  • Interleukin-1 / genetics
  • Interleukin-10 / genetics
  • Interleukin-4 / genetics
  • Interleukin-6 / genetics
  • Interleukins / genetics*
  • Leukocytes, Mononuclear / enzymology
  • Leukocytes, Mononuclear / immunology
  • Male
  • Matrix Metalloproteinase 1 / genetics
  • Matrix Metalloproteinase 13
  • Matrix Metalloproteinase 3 / genetics
  • Matrix Metalloproteinases / genetics*
  • Middle Aged
  • RNA, Messenger / analysis
  • Reverse Transcriptase Polymerase Chain Reaction
  • Synovial Fluid / chemistry
  • Synovial Fluid / enzymology
  • Synovial Fluid / immunology
  • Tumor Necrosis Factor-alpha / genetics*

Substances

  • Antirheumatic Agents
  • Antisense Elements (Genetics)
  • Interleukin-1
  • Interleukin-6
  • Interleukins
  • RNA, Messenger
  • Tumor Necrosis Factor-alpha
  • Interleukin-10
  • Interleukin-4
  • Collagenases
  • MMP13 protein, human
  • Matrix Metalloproteinase 13
  • Matrix Metalloproteinases
  • Matrix Metalloproteinase 3
  • Matrix Metalloproteinase 1